In the CC q&a, patients were asked to journal sensitivities/AE's. Still lots of uncertainties, but he says most discontinuations due to nausea and not GI issues. Seems plausible that patients coming on to new obesity trials maybe quite different than earlier drug generations trials. More risk adverse, probably more fearing of needles or sc drugs period. I was seeing an ortho surgeon recently that assumed I had to be convinced to go for shoulder MRI with contrast and he went into what could have been a long winded explanation of why he wanted contrast. I stopped him and told him "contrast is good". I guess people are generally concerned about getting any sc molecules while eating all sorts of junk while getting tattooed. I am not sure how GLP companies will address this issue in trials that already have commercially available earlier generation drugs.
Market Data 
Markets 
AI
